Search results
Gilead (GILD) Up as Twice-Yearly HIV Shot Prevents Infection
Zacks via Yahoo Finance· 1 day agoGilead's (GILD) twice-yearly, subcutaneous lenacapavir has demonstrated its potential as a new tool...
3 High-Yield S&P 500 Dividend Stocks Down More Than 25% to Buy Now and Hold for at Least a Decade |...
The Motley Fool· 7 days agoThe S&P 500 is up an incredible 25% over the past 12 months, but not every stock in the benchmark...
Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday? - BioNTech (NASDAQ:BNTX)
Benzinga· 5 days agoAlso Read: What’s Going With BioNTech Stock On Monday? The partial hold affects the enrollment of new patients in the trial in the U.S., BioNTech said in an SEC filing.
Here's Why Eli Lilly (LLY) is Probably the Best Drug Stock Now
Zacks· 2 days agoOf these, at present, Eli Lilly appears to be a great stock to have in one’s portfolio based on its strong overall financial performance and robust drug pipeline. Lilly, with ...
Sarepta Gains as FDA Official Overrules Staff to Approve Therapy
Bloomberg via Yahoo Finance· 23 hours ago...slows overall progression of the disease.Most Read from BloombergCDK Hackers Want Millions in...
Sarepta Stock Surges on Expanded Elevidys Approval. It’s a ‘Best-Case’ Scenario for Shares.
Barrons.com· 24 hours agoThe biopharmaceutical company says the drug was approved for ambulatory and non-ambulatory people,...
Sarepta’ stock soars 38% after FDA expands approval for DMD drug
Market Watch· 1 day agoDuchenne muscular dystrophy is a genetic disease that primarily affects boys and causes muscle...
Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy
Investor's Business Daily· 18 hours agoSarepta stock rocketed Friday after hitting a "grand slam" approval that expands the market for its...
FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
Zacks via Yahoo Finance· 23 hours agoFollowing the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation...
Sarepta Skyrockets After FDA Signs Off On Duchenne Gene Therapy
Investor's Business Daily· 1 day agoLast year, the FDA granted the Sarepta Therapeutics (SRPT) gene therapy, dubbed Elevidys, an accelerated approval for children ages 4 and 5 with Duchenne muscular dystrophy. Now Thursday night ...